Prescriptions Of Anti-Obesity GLP-1 Medications For Adolescents Increased 1.5-Fold Between 2023 & 2024 

Prescriptions of one of the two anti-obesity GLP-1 medications approved for use by adolescents ages 12 to 17 in the United States increased 1.5-fold, from 9.9 per 100,000 in 2023 to 14.8 per 100,000 in 2024, according to a recent study. During 2024, first-time prescriptions of semaglutide as an anti-obesity medication (brand name Wegovy) were 17.7-fold higher than first-time prescriptions for liraglutide (brand name Saxenda).;;

The findings were reported in FDA-Approved Anti-Obesity GLP-1 RA Prescription Trends Among Adolescents by researchers with Truveta . . .